| Drug Name |
Tedizolid phosphate |
| Drug ID |
BADD_D02136 |
| Description |
Drug-resistant bacteria, such as methicillin-resistant _Staphylococcus aureus_, vancomycin-resistant _Enterococcus faecium_, and penicillin-resistant _Streptococcus penumoniae_, represent a massive public health threat.[A199086, A199131] Tedizolid is a member of the oxazolidinone class of antibiotics, which includes the previously approved [linezolid] and is generally effective against multidrug-resistant Gram-positive bacteria. Tedizolid is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and is generally more effective and more tolerable than [linezolid].[L11232, A199086, A199050]
Tedizolid was approved by the FDA on June 20, 2014, for sale by Cubist Pharmaceuticals as tedizolid phosphate (SIVEXTRO®). This product is currently available as both an oral tablet and as a powder for intravenous injection.[L11232] |
| Indications and Usage |
Tedizolid Phosphate is an oxazolidinone antibacterial drug indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin-resistant [MRSA] and methicillin-susceptible [MSSA] isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus Group (including Streptococcus anginosus, Streptococcus intermedius, and Streptococcus constellatus), and Enterococcus faecalis. |
| Marketing Status |
Prescription |
| ATC Code |
J01XX11 |
| DrugBank ID |
DB09042
|
| KEGG ID |
D09686
|
| MeSH ID |
C515040
|
| PubChem ID |
11476460
|
| TTD Drug ID |
D0DI6L
|
| NDC Product Code |
66406-0206; 68225-066; 67919-041; 65392-2912; 67919-040; 72000-310; 42765-022; 72000-320 |
| Synonyms |
tedizolid phosphate | torezolid phosphate | TR 701 | TR-701 | DA 7218 | DA7218 | DA-7218 | Sivextro |
